Dr. Thubrikar is a world-renowned authority on the aortic valve. He previously worked as Director of BME at South Dakota School of Mines and Technology; as Edwards Distinguished Research Scientist at Edwards Lifesciences Corp.; as Director of BME at The Heineman Medical Research Center; and as Director of Surgical Research in the Department of Surgery at UVA. Dr. Thubrikar authored “Vascular Mechanics and Pathology” and “The Aortic Valve”.

Mr. Evans assembles and tests Optimum TAV, helps improve our delivery catheters, and assists in pre-clinical studies. Previously, he researched interactions between human anatomy and peripheral arterial stents in the femoro-popliteal region , and the development of the heart and its greater vasculature in the mouse model using different genetic approaches. He has also worked as an animal specialist for World Heart, Inc.

Dr. Wadke is familiar with contemporary cGMP requirements, including the generation of technical data packages for the U.S. and OUS regulatory filings. In 1994, he retired from BMS after 25 years there, most recently as Director of R&D. Through 2012, he consulted PhRMA, generic and start-up companies globally in product development and regulatory compliance. Dr. Wadke consults part-time for Company.

Mr. Wadke leads the strategic operations of the Company with over 19 years of cross-functional experience. Prior to the Company, he consulted for early-stage pharmaceutical companies. From 2007-2009, he worked for VGX Pharma in Business Development, including its integration of an acquisition and its merger with Inovio BioMedical (NYSEMKT:INO). He previously worked in financial, marketing, and strategy roles at J.P. Morgan and MB Financial.

Mr. Heble is a registered patent attorney with significant experience handling intellectual property matters related to a wide range of life science-based technologies. Mr. Heble began his legal career with an Am Law 100 law firm, and most recently held the position of Senior Patent Counsel for a Fortune 500 consumer products company.

Mr. Parate has over 20 years of entrepreneurial and management experience in the financial industry. He began his career at Susquehanna International Group, and has since co-founded multiple trading firms. He is the Company's largest investor, and consults part-time for the Company.

Dr. Zhu is President and Founder of CCRF, a leading CRO for medical devices focused on interventional cardiology in China. Wide Line Limited is the main shareholder of CCRF. He has over 20 years of medical device experience. He has also co-founded start-up companies for interventional cardiology devices and serves as a Board Member to multiple medical companies. He holds an MBBS and an MBA.